

# International Cancer Research Partnership

Welcome & Introduction

14 May 2024

Nigel Brockton

Lynne Davies




# ICRP mission

---

International Cancer Research Partnership (ICRP) is a **unique alliance of cancer organizations working together to enhance global collaboration and strategic coordination of research.**

# ICRP mission – what we do



*Add value to cancer research efforts internationally by fostering **collaboration** and **strategic coordination** between cancer research organizations.*



Active, international trusted network of **over 160** cancer research funding organizations

Monthly webinars  
Annual & Virtual meetings



Share data: Online research portfolio on ICRP website



Provide Analytical tools for data analyses

- Individual partner analysis
- National and international analysis



Share information on research evaluation, grants management



Forum for coordination and collaboration



# ICRP mission – Monthly Meeting topics

## Impact of cancer on the economic wealth of adult cancer survivors

### Review objective:

- Describe the evidence on the effect of a cancer diagnosis on all sources of income of individuals diagnosed with cancer during adulthood, regardless of their employment or financial status.

### Review rationale:

- Focus of previous evidence syntheses:
  - Return to work, productivity loss – labour force activity
  - Financial toxicity/burden – out-of-pocket expenses
- Our review
  - Include sources of income outside the workplace (e.g., investments, welfare benefits, debt)
  - Separate and analyze categories of income

- Presentations on topics of interest, e.g. new strategies & initiatives
  - Updates on workstreams

## Novel Interventions for Chronic HPV Infection and HPV-associated IntraEpithelial Neoplasia (NICHE)

Philip E. Castle, PhD, MPH

Director, Division of Cancer Prevention

Senior, Tenured Investigator, Division of Cancer Epidemiology and Genetics

NCI, NIH, DHHS

philip.castle@nih.gov



## ICRP Partner Presentation

Doug Perin, ICSN Program Coordinator  
on behalf of the ICSN Steering Committee



April 8, 2022



## ICRP Partner Presentation: “Artificial Intelligence Enabled Radiation Treatment Planning for Low- and Middle-Income Countries”

Dr H. Timothy Hsiao (ASTRO) introducing Dr Laurence Court (MD Anderson) and Dr Alex Alencar (Rising Tide Foundation for Clinical Cancer Research)



# ICRP Website & Database

[www.icrpartnership.org](http://www.icrpartnership.org)



Log in

Follow Us [in](#) [t](#)  Powered by [Google Translate](#)

[Home](#) [About Us](#) [ICRP Data](#) [ICRP Map](#) [Join ICRP](#) [Funding Opportunities](#) [Library](#)



**Connect**  
Connect with senior representatives of international cancer research organizations.

Established in 2000, International Cancer Research Partnership (ICRP) is a unique alliance of cancer research funding organizations, working together to enhance global collaboration and strategic coordination of research.

## What We Do

ICRP's partners are an active network of cancer research funding organizations, working together to enhance global collaboration. ICRP maintains the only public source, worldwide, of current and past grants, totalling over \$80 billion in cancer research since 2000 from **32 ICRP Partners** and **166 international funding organizations**.

## What You Can Do

You can search the **interactive ICRP map database** to determine which funders are funding research in a particular cancer site topic, find other organizations or researchers around the world to collaborate with, and the portfolio to plan informed, non-duplicate research questions.

## ICRP Map

Click on the map below to find out more about global cancer research projects and international collaborations. Refer to the [website user guide](#) for further information or [contact us](#) if you have any questions.

Search Criteria: All Total Projects: 372,970 (w/ PI: 372,970, w/ Collabs.: 8,283)



Total 8 entries



Log in

Follow Us [in](#) [t](#)  Powered by [Google Translate](#)

[Home](#) [About Us](#) [ICRP Data](#) [ICRP Map](#) [Join ICRP](#) [Funding Opportunities](#) [Library](#)

## Search ICRP Database

This search page features a variety of criteria to allow the user to access and manipulate the data contained in the ICRP database. Users should be aware that data contained in the ICRP database is updated throughout the year, and due to differing data upload schedules, recent years may not yet include all partner and associate organizations' data. Refer to the [website user guide](#) for further information or [contact us](#) if you have any questions.

Search Terms

- All of the keywords
- None of the keywords
- Any of the keywords
- Exact phrase provided

### Year Active

Use this indicator to search for awards that are active during the time period you have selected.

### Project Award Code

Institutions and Investigators


Funding Organizations

Cancer and Project Type

Common Scientific Outline - Research Area

All projects are shown below. Use the form on the left to refine search results Total Base Projects: 138,793 / Total Projects: 372,970

### Projects by PI Country




### Projects by CSO



### Projects by Cancer Type



### Projects by Type



Projects -

Data Completeness




[View ICRP Map](#)

| Project Title                                   | PI | Institution                            | Ctry. | Funding Org. | Award Code         |
|---|----|--|-------|--------------|--------------------|
| Synthesis of Selected Chemical Carcinogen...    |    | MRIGlobal                              | US    | NCI          | CB037127           |
| STERKK- Oncologisch revalidatieprogramma...     |    | AZ Groeninge                           | BE    | KBF          | 2023-11121310-2... |
| Valideren vragenlijst depressieve symptom...    |    | AZ Groeninge                           | BE    | KBF          | 2023-11121310-2... |
| Task Order 1A, Task Area 1: Project Kickoff ... |    | Essex Management, LLC                  | US    | NCI          | 75N91022D00015     |
| IPA support                                     |    | Sarasota County Public Hospital Dis... | US    | NCI          | 6474224            |

Provided by the US NCI Center for Global Health, with funding support from the CDMRP



# ICRP initiatives – Understanding the cancer research landscape



## Intelligence for the cancer research community



- Strategic Planning
- Address gaps
- Opportunities to collaborate

## Recent papers on trend analyses:

special articles

ECONOMIC ANALYSIS

### Trends in International Cancer Research Investment 2006-2018

Rachel Abudu, BS, MPH<sup>1</sup>; Gauthier Bouche, MPH, MD<sup>2</sup>; Karima Bourougaa, PhD<sup>3</sup>; Lynne Davies, PhD<sup>4</sup>; Kalina Duncan, BS, MPH<sup>5</sup>; Carla Estaquio, PhD<sup>6</sup>; Anna Diaz Font, PhD<sup>6</sup>; Marc S. Hurlbert, PhD<sup>7</sup>; Paul Jackson, PhD<sup>8</sup>; Linda Kroeskop-Bossenbroek, PhD<sup>9</sup>; Ian Lewis, PhD<sup>10</sup>; Giota Mitrou, PhD<sup>6</sup>; Abdul Mutabbir, BSc<sup>10</sup>; Christopher A. Pettigrew, PhD<sup>11</sup>; Lynn Turner, PhD<sup>12</sup>; Annemarie Weerman, PhD<sup>9</sup>; and Kari Wojtanik, PhD<sup>13</sup>

The Lancet Oncology Commission

Check for updates

## European Groundshot—addressing Europe’s cancer research challenges: a *Lancet Oncology* Commission

Mark Lawler, Lynne Davies, Simon Oberst, Kathy Oliver, Alexander Eggermont, Anna Schmutz, Carlo La Vecchia, Claudia Allemani, Yolande Lievens, Peter Naredi, Tanja Cufer, Ajay Aggarwal, Matti Aapro, Kathi Apostolidis, Anne-Marie Baird, Fatima Cardoso, Andreas Charalambous, Michel P Coleman, Alberto Costa, Mirjam Crul, Csaba L Dégi, Federica Di Nicolantonio, Sema Erdem, Marius Geanta, Jan Geissler, Jacek Jassem, Beata Jagielska, Bengt Jonsson, Daniel Kelly, Olaf Kelm, Teodora Kolarova, Tezer Kutluk, Grant Lewison, Françoise Meunier, Jana Pelouchova, Thierry Philip, Richard Price, Beate Rau, Isabel T Rubio, Peter Selby, Maja Južnič Sotlar, Gilliosa Spurrier-Bernard, Jolanda C van Hoeve, Eduard Vrdoljak, Willien Westerhuis, Urszula Wojciechowska, Richard Sullivan



original reports

HEALTH SERVICES RESEARCH

### Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities

Lynne Davies, PhD<sup>1</sup>; Danny A. Milner Jr, MD<sup>2</sup>; Lawrence N. Shulman, MD<sup>3</sup>; Lynnette Kyokunda, PhD<sup>4</sup>; Alemayehu Bedada, MD<sup>4</sup>; Peter Vuylsteke, MD<sup>4</sup>; Nestory Masalu, MD<sup>5</sup>; Paul Jackson, PhD<sup>6</sup>; Natanya Jennings, PharmD<sup>7</sup>; Adesumbo Odunlami, PharmD<sup>7</sup>; Phangisile Mtshali, PGDipPM<sup>8,(1)</sup>; and Ute Dugan, MD, PhD<sup>9</sup>

Check for updates

- 2006-2018 world trends: *Journal of Global Oncology* (April 2021) <https://doi.org/10.1200/GO.20.00591>
- Lancet Commission on cancer research in Europe (Nov 2022) [https://doi.org/10.1016/S1470-2045\(22\)00540-X](https://doi.org/10.1016/S1470-2045(22)00540-X)
- Analysis of Cancer Research Projects in Sub-Saharan Africa (Jun 2023) <https://doi.org/10.1200/go.22.00203>




# From data to action: Prevention & Early Detection

## ICRP data

- Cancer Type: all
- CSO: 3



Consistently low investment in CSO3: primary prevention



## Results

## Actions

Home - Latest - News and updates - New funding partnership with Cancer Australia

## New funding partnership with Cancer Australia

This exciting new collaboration will enable us to co-fund cancer research in Australia.

14 September 2020

World Cancer Research Fund International (WCRF International) and Cancer Australia are pleased to announce their new collaboration.

As part of the 2020-21 WCRF International grant programme, we have partnered with Cancer Australia to co-fund vital cancer prevention research in Australia. This opportunity to be funded by both WCRF International and the Australian government, through Cancer Australia, will be available to applicants based in Australia who are investigating the role of diet, nutrition (including body composition) and physical activity in primary cancer prevention.


# Current focus: Metastatic Breast Cancer

## ICRP data

- Cancer Type: Breast Cancer
- CSO: multiple
- Keywords: metastasis



Figure 8a: MBC Research Grants Studying Integrins and Cadherins from 2000 - 2013




## Results

MBC focused research made up only 7% of the \$15-billion invested in breast cancer research from 2000 to 2013 by the major governmental and nonprofit funders from North America and the United Kingdom.

There is a paucity of research in MBC cancer control, outcomes, and survivorship.

## Actions

Individual organizations increase funding, e.g. Komen Metastatic Breast Cancer Collaborative Research Initiative 

New collaborative funding partnerships: 



2023-24:

- What targets are being pursued in MBCA?
- Is research focussed on patient priorities?
- Updated analysis & publication

# Current focus: Survivorship / Living with and beyond cancer

## In progress: (completing 2024)

- Investment trends
- Does research match patient priorities?

### NCI - Challenges That Cancer Survivors Face

- Reduced quality of life
- Emotional distress (depression, anxiety/uncertainty, altered body image, survivor's guilt)
- Difficulty maintaining or finding employment
- Economic burden (financial toxicity)
- Denial of health and/or life insurance
- Risk of recurrence
- Increased risk of second primary cancer
- Treatment side effects (cardiotoxicity, cognitive challenges)
- Physical problems
- Loss of fertility and/or diminished reproductive health
- Barriers to health care (high insurance and out-of-pocket costs for health care)
- Barriers to health care (lack of coordination of health care, and limited access to specialty care)




### NCRI - Distilled priorities

- Mental health - Emotional and psychological support needs for people living with cancer
- Lifestyle - More information about how lifestyle changes can help people in treatment and beyond
- Multiple conditions - Better support and treatment for cancer patients with multiple medical conditions
- Side effects - how to prevent and treat side effects from cancer treatment
- Communication - Clearer communication about cancer so we all feel more informed

### CCRA - Research Focus

- Psychological effects
- Quality of life
- Social needs / social support
- Economic sequelae
- Thanatological issues (end of life - social, psychological issues)
- Physiological effects
- Care delivery, access and quality



- Low resource settings
- Childhood cancer survivorship research



# Current focus: Childhood cancer

## In progress: (completing 2024)

- Investment trends, especially in rare / low survival cancers (e.g. DIPG)
- ‘Funders Dashboard’ – is research activity increasing? Is it having an impact?

### Trends in international investment in childhood, adolescent and young adult (CYA) brain tumor research 2006-2018, with a focus on diffuse intrinsic pontine glioma (DIPG)

Author: Weinstein A, on behalf of the Coalition Against Childhood Cancer (CAC2) and the International Cancer Research Partnership (ICRP)

**Introduction:**


Organizations funding brain tumor research want to identify gap areas for funding individually or in collaboration and want to better understand existing research focus in order to maximize new project investments. The International Cancer Research Partnership (ICRP) and the Coalition Against Childhood Cancer (CAC2) used international research portfolio, publication and trials data to assess the landscape of CYA brain tumor and DIPG research. DIPG originates in the brain stem, from glial cells and can be low (I-II) or high (III-IV) grade at diagnosis. Biopsy is challenging due to the location of the tumor and it is most often diagnosed by MRI appearance. DIPG accounts for roughly 10% of all childhood brain tumors,<sup>1</sup> and the peak occurrence is between 5 and 10 years of age. Common symptoms include problems with balance, walking, eyesight, swallowing, nausea, vomiting, headache and facial weakness. Radiation therapy is typically the primary therapy but is rarely curative and 5 year survival is only 2%.<sup>6</sup> Other treatments include chemotherapy, biological agents and surgery (although the tumor location makes the latter difficult).

**Methods:**

Data for projects wholly-relevant to CYA and active on or between the calendar years 2006 to 2018 were extracted from the ICRP database<sup>1</sup> and trends based on the 2018 exchange rate to USD to ensure that trends did not reflect fluctuations in exchange rates. Data on publications relevant to DIPG were extracted from PubMed<sup>2</sup> and clinical trial information sourced from ClinicalTrials.gov<sup>3</sup> and the International Clinical Trials Registry Platform<sup>4</sup> over the same time period. Publication and project data relating to DIPG were identified using combinations of keyword vectors and manual curation.


**Results:**

From 2006-2018, investment in brain tumor research increased from \$13m to \$73m (an above inflation increase), and investment also increased as a percentage of the CYA portfolio (Fig. 1). Brain tumor research received the highest percent investment (30%) in 2018.



References:  
 1. <https://www.dipg.org/dipg-facts/> (Accessed 12 October 2021)  
 2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930108/> (Accessed 01 March 2021)  
 3. <https://www.clinicaltrials.gov/> (Accessed 01 March 2021)  
 4. <https://www.who.int/clinical-trials-registry-platform/> (Accessed 31 March 2021)  
 5. <https://www.dipg.org/dipg-facts/dipg-survival-rate-and-prognosis/> (Accessed 01 March 2021)  
 6. <https://www.dipg.org/dipg-facts/dipg-survival-rate-and-prognosis/> (Accessed 04 June 2021)

Research into treatment had risen (from \$6m to \$38m) as had research into biology (from \$3m to \$19m) - an essential foundation for future personalized treatments. Given the lifelong impact on survivors it was encouraging that survivorship research investment had also started to increase. While 5-year survival for CYA cancers is now over 80%, survival for Diffuse Intrinsic Pontine Glioma (DIPG) remains very low. To assess capacity for future progress, several indicators were considered. The number of new DIPG projects per year increased from an average of 3 per year (2006-2012) to 11 (2013-2018) and funding increased from \$0.5m (2006) to \$10m (2018) (Fig. 2).



Also, by 2018, 9 projects included a training component to build future research capacity. The number of laboratories researching DIPG increased from 2 in the US (2006) to 53 institutions in 6 countries (2018). Recent years had seen increased funding for pre-clinical models essential for identifying new targets. Collaborative initiatives such as DIPG-Open and DIPG-All had been funded to collect biological samples and accelerate translation of therapeutics to the clinic.

#### DIPG Research Funders' Dashboard

|   |  |
|---|--|
| <p><b>Is funding for research increasing?</b></p> <p>Funding increased from \$0.5m in 2006, to \$10.3m in 2018.</p>   | <p><b>Is international trials and data infrastructure available?</b></p> <p>Only 4 of 102 studies focussed exclusively on DIPG and only 13 recruited internationally. The Accelerate Program facilitates international cooperation.</p>                        |
| <p><b>Is the number of laboratories/PIs active in this field increasing?</b></p> <p>In 2006, only two labs were funded by ICRP partners in the US. In 2018, 53 institutions in 6 countries were funded.</p>   | <p><b>Are biobanks/model systems funded and accessible?</b></p> <p>There has been increased funding for model systems and collaborative funding for initiatives such as DIPG-Open and DIPG-All to collect biological samples &amp; accelerate translation.</p> |
| <p><b>Is survival increasing?</b></p> <p>Data<sup>5</sup> suggests 2-year survival is approximately 10% and 5-year survival is approximately 2% (up from 1%), but this is still very low.</p>   | <p><b>Is there evidence that research collaboration is increasing?</b></p> <p>Publication analysis<sup>2</sup> suggested that 65% of DIPG publications arose from collaborations, and 27% arose from international research collaborations.</p>                |
| <p><b>Are training grants being funded for new researchers in the field?</b></p> <p>In 2006, 0 awards were classed as "Training", but in 2018, 9 projects included a training component (all funded by the US government). Need to ensure that early careers in DIPG are supported.</p> |  |

**Conclusions:**  
 The increase in investment in brain tumors and in DIPG in particular over this time-frame is encouraging. However, despite evidence<sup>5</sup> that 5-year survival for DIPG has improved from 1% to 2%, clearly major advances need to be made in new treatments and monitoring the funding landscape carefully to make strategic investments will be essential. National and international cooperation at the researcher and funder level are key.

# Sharing resources and strategies

Forum available for questions

**ICRP**  
International Cancer Research Partnership

### Survey of the Impact of COVID-19 on Cancer Research Funders

Visit [www.icrpartnership.org](http://www.icrpartnership.org) for more results from the survey

In our survey, 75% of respondents reported that their funding to support cancer research would decrease this year

#ICRP2020  
#WorldCancerResearchDay

[https://www.icrpartnership.org/library/file/7909/ICRP\\_Newsletter\\_Sept2020.pdf](https://www.icrpartnership.org/library/file/7909/ICRP_Newsletter_Sept2020.pdf)



Home About Us ICRP Data ICRP Map Join ICRP Funding Opportunities Library

## Funding Opportunities

Our partners' latest funding opportunities are advertised below – the most recent opportunity is at the top of the list. Please scroll down for further opportunities and note that deadlines are included in the text of the post. Click on the links in the funding announcement section at the right to find general information about funding schemes offered by each of our partner organizations.

### Latest Announcements

| Topic  | Funding Announcements   |
|--|---|
| <b>Worldwide Cancer Research - Project Grant Round now open!</b> | If you have a novel and exciting idea that could help to prevent, diagnose, or treat cancer our funding could help make your idea a reality. <b>Our Grant Round is now OPEN so you can apply for funding. Applications will close on 2nd April so don't miss this opportunity.</b> Our focus is on early-stage discovery research, offering project grants of up to <b>£275,000 and 12-36 months</b> in length. We're looking for basic, fundamental, or translational research into the prevention, diagnosis, or treatment of <b>any type of cancer and from any country.</b><br><a href="https://www.worldwidecancerresearch.org/for-researchers/">https://www.worldwidecancerresearch.org/for-researchers/</a><br>By Lynn Tamer 2 months ago  |
| <b>INSPIRE Research Challenge 2024 call</b>                      | WCRF International, in partnership with American Institute for Cancer Research, World Cancer Research Fund and Wereld Kanker Onderzoek Fonds has launched the INSPIRE Research Challenge 2024 call. This will prioritise innovative, bold, and creative proposals with the potential to catalyse rapid and impactful advances in cancer prevention, treatment and survivorship.<br><b>Eligibility:</b> <ul style="list-style-type: none"><li>The programme is open to early career individuals – defined as not less than 2 years, but not more than 6 years post-doctoral degree (PhD or MD research) from anywhere in the world</li><li>Applicants must be employed on a research contract within a department at a research institution affiliated with a university or medical school.</li><li>Proposed projects must have direct relevance to cancer prevention, treatment or survivorship and may address any or all stages of the cancer journey.</li><li>Research should address worldwide factors including health inequality...</li></ul> |

### Funding Announcements & Feeds

Links to pages giving our partners' general funding announcements for cancer researchers are included below, where available. Organizations are listed alphabetically. Where an organization has a specific focus that is not evident from the name, this is noted in brackets after the name. Organizations marked (CC) have a specific focus on childhood cancer. If you have any questions, please contact us.

**Australia**

- Cancer Australia<sup>††</sup>
- Cancer Institute New South Wales<sup>††</sup>
- National Breast Cancer Foundation<sup>††</sup>

**Belgium**

- Anticancer Fund<sup>††</sup>

**Canada**

- Alberta Cancer Foundation<sup>††</sup>
- Alberta Innovates<sup>††</sup>
- Brain Tumour Foundation of Canada<sup>††</sup>
- Breast Cancer Society of Canada<sup>††</sup>
- Canada Research Coordinating Committee<sup>††</sup>
- Canadian Association of Radiation Oncology<sup>††</sup>
- Canadian Cancer Society<sup>††</sup>
- Canadian Institutes of Health Research<sup>††</sup>

**Thank you!**